Streptococcal pyrogenic exotoxin F (SpeF), previously referred to as mitogenic factor, is a newly described potent mitogen produced by group A streptococci. To investigate whether this protein belongs to the family of microbial superantigens, we analyzed the cellular and molecular requirements for its presentation to T cells and compared it with the known streptococcal superantigen pyrogenic exotoxin A (SpeA) and the nonspecific polyclonal T-cell mitogen phytohemagglutinin (PHA). SpeF and SpeA were efficiently presented by autologous antigen-presenting cells (APCs) and an allogeneic B lymphoma cell line, Raji. In contrast, the monocytic cell line U937, which does not express major histocompatibility complex (MHC) class II molecules, failed to present SpeF as well as SpeA but supported the response to PHA. Thus, the presentation of SpeF by APCs was class II dependent but not MHC restricted. The requirement for HLA class II was further supported by the ability of anti-HLA-DQ monoclonal antibody to block the SpeF-induced proliferative response by 75 to 100%c. Paraformaldehyde (PFA) fixation of autologous APCs resulted in an impaired ability of SpeF and SpeA to induce optimal T-cell proliferation. In contrast, fixation of Raji cells did not affect the induced proliferation. The stimulatory effect of PHA remained unaffected by both the use of PFA-fixed APCs and the addition of the HLA class TI-specific monoclonal antibodies. The addition of a supernatant enriched in interleukin 1 and interleukin 6 to fixed autologous APCs resulted in an increased SpeF-induced response; thus, the impairment was not due to a requirement for processing, but, rather, costimulatory factors produced by metabolically active APCs were needed. SpeF was found to preferentially activate T cells bearing VD 2, 4, 8, 15, and 19, as determined by quantitative PCR. The data presented clearly show that SpeF is a superantigen. We also studied the prevalence of the speF gene in clinical isolates by Southern blot analyses, and the gene could be detected in 42 group A streptococcal strains, which represented 14 serotypes.
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Superantigens are a group of microbial proteins which are very powerful immunomodulators. The bacterial superantigens include, among others, the Staphylococcus aureus enterotoxins (1, 33) and toxic shock syndrome toxin 1 (1, 33) as well as the streptococcal pyrogenic exotoxins A, B, and C (SpeA, -B, and -C) (1) , the cell surface M protein (49) , and the recently identified streptococcal superantigen (SSa) (36) , all produced by group A streptococci (GAS).
Superantigens induce massive T-cell proliferation; 5 to 40% of the cells become activated, which can be compared to approximately 0.001% for a conventional antigen (30) . Their capacity to activate such a large T-cell population is due to their ability to cross-link the relatively invariable parts of the major histocompatibility complex (MHC) molecule on antigen-presenting cells (APCs) and the T-cell receptor (TCR) of the T cells without prior internalization and processing by the APC (10, 11, 23, 33, 35, 44, 51) . Superantigens are presented to T cells by APCs that express MHC class II molecules in an MHC-unrestricted manner. Superantigens interact with the variable region of the T-cell receptor ,3 chain, and each superantigen has affinity for a set of V,B elements (9, 23, 32, 33) . This results in a preferential expansion of all T cells bearing those specific V,B elements, which is followed by a high production of cytokines (2, 8, 16, 17, 26, 40, 52) . The superantigen-induced overproduction of cytokines is believed to strongly influence the development of toxic shock syndrome (16, 17, 30, 33, 40, 43, 46) .
SpeA and SpeC show high structural homology with each other but no significant homology with SpeB (14) . Furthermore, SpeA and SpeC have been shown to be encoded by bacteriophages, while SpeB is chromosomally encoded (15, 24, 25) . SpeB also has cysteine proteinase activity and can as such convert precursor interleukin 1, (IL-13) to mature IL-1i (18, 28) . The Spes share many biological activities, such as pyrogenicity, mitogenicity, enhancement of host susceptibility to endotoxin shock, and superantigenicity (1, 29, 53, 55) . A novel mitogenic factor, called MF, expressed by GAS has been reported recently (22) . The nucleotide sequence of MF did not reveal any significant homology with the Spes or any other known proteins. However, the MF protein induced a cytokine production profile similar to that of the Spes, and nanogram concentrations were sufficient for induction of a massive T-cell response, which indicated that MF might exhibit superantigenic activity (40) . Even though pyrogenicity tests of MF have not been performed, we argue that the protein is a pyrogenic exotoxin on the basis of the massive induction of pyrogenic cytokines noted in vitro, and therefore the protein is renamed SpeF in accordance with the other streptococcal exotoxins. The clinical relevance of SpeF has been shown by analyses of neutralizing antibodies in sera from patients with streptococcal toxic shock syndrome (STSS) or uncomplicated infections (41) . The study showed a correlation between the low neutralizing capacity of SpeB and SpeF mitogenicity and severe infections (41) during 1976, 1980-1981, 1984-1985, and 1988-1989 (38) Serotyping of GAS strains. T typing was performed by agglutination with T type-specific antisera from the Institute of Sera and Vaccines, Prague, The Czech Republic (13) . To further discriminate between the T types, a serum opacity reaction test was performed as described previously (34) .
Antigens. SpeF was purified from a clinical GAS (Boehringer-Mannheim), and 2.5 U of Taq DNA polymerase (Boehringer-Mannheim). The gene was amplified by one denaturation cycle of 94°C for 1 min and then 30 cycles of 94°C for 1 min, 50°C for 1 min, and 72°C for 2 min, and one cycle of 72°C for 3 min. This PCR product (1 ,ul) was used as the template in a second PCR, which was run for 25 cycles at an annealing temperature of 53°C but otherwise as described above.
speA and speB were also amplified by using chromosomal DNA from SF130 and from a clinical Swedish isolate, TlBW (38) , as templates in the respective PCRs. The oligonucleotides and reaction conditions for speA and speB amplification have been described previously in detail (38) . A booster PCR was performed for detection of the speA gene in strains that were negative for speA by Southern blot analyses. The gene was first amplified as described previously (38) , and 1 ,ul of this PCR product was used as a template in a booster PCR which was run for 25 cycles at an annealing temperature of 50°C but otherwise as described previously (38) . Southern Kotb et al. (32) . Quantification of the PCR products were accomplished by use of 5'-32P-labelled primers for the C3 and the Co. chains. The Cao cDNA was coamplified with the VP cDNA and used as an internal control. Radiolabelled PCR products were separated on 2% agarose gels and exposed on X-ray films. The relative amounts of Ca and V,B were determined by scanning the autoradiograms and integrating the relevant peaks. The PCR values were normalized by dividing the area of the VP peak by the area of the Ca peak.
To determine the specific expansion, the normalized V,B value for SpeF-stimulated cells was then divided by the corresponding V,B value obtained after anti-CD3 stimulation. The PCR value is described by the following equation: PCR value = (area of V,Bn/area of Ca)speF/(area of V3n/area of Ca)anti-cD3, where n equals V,B family number 1 to 20. Ratios greater than one indicate specific expansion of particular VP elements.
RESULTS AND DISCUSSION
Superantigens have generated a lot of attention during recent years, in part because of their potential role in both autoimmunity and manifestations in acute infections. The toxic shock syndrome caused by S. aureus has been shown to be mediated by the superantigen toxic shock syndrome toxin 1 (6, 48) and the Spes have been implicated in the development of STSS caused by GAS (19, 20, 37, 47, 54) .
Although the biological activities of SpeF strongly suggested superantigenic properties of the protein, further studies were required to verify this. To APC requirement for induction of T-cell proliferation by SpeF. The requirement of SpeF for APCs to induce T-cell proliferation was analyzed by cell culture experiments using autologous APCs and Raji cells. Both cell types functioned as accessory cells for SpeF-induced T-cell proliferation ( Fig. 1A and 2), which indicated a lack of MHC restriction in presentation of this molecule. However, paraformaldehyde fixation of autologous APCs resulted in an impaired presentation of both SpeF and SpeA (Fig. 1A and B) . The proliferative response to SpeF was decreased by 75 to 100%, and that to SpeA was decreased by 67 to 96%. In comparison, when APCs were treated with paraformaldehyde, a mild decrease in PHAinduced proliferation was noted in two of the three experiments (Fig. 1C) . However, fixation of Raji cells did not affect their ability to function as accessory cells. This is in accordance with other studies reporting an impairment of superantigen activity by fixation of autologous APCs (50) , while fixed Raji cells were functional as accessory cells (9, 50) . Raji cells express class II molecules on their surface as well as constitutive high levels of the costimulatory molecule B7 and membrane-bound cytokines (3); as proposed by Tomai et al. (50) , this could be the reason for their function as accessory cells even when they are metabolically inactive. Tomai et al. (50) also reported that the impairment of superantigen stimulation could be overcome by the addition of recombinant IL-1 and recombinant IL-6; this argued for a role of costimulatory factors normally produced by active APCs. We obtained similar results with cell culture experiments with fixed autologous APCs where both the SpeA-and SpeF-induced proliferative responses were increased by the addition of a cell supernatant enriched in IL-1 and IL-6. Thus, the impairment in SpeF ability to induce T-cell proliferation when fixed APCs were used was not due to the requirement for cellular processing but rather to the need for costimulatory factors.
SpeF requires HLA class II molecules for T-cell activation. The monocytic cell line U937, which lacks class II molecules on its cell surface, was also tested as accessory cells and was found to be nonfunctional for SpeF or SpeA presentation but functional for PHA stimulation (Fig. 2) . This was indicative of a requirement for class II molecules in SpeF-induced T-cell activation. Further support for class II dependence was obtained by blocking HLA class II molecules on APCs with class II-specific monoclonal antibodies. The experiment showed an almost complete inhibition of SpeF-induced proliferation (75 to 100%) by a class II DQ-specific monoclonal antibody as compared with that of untreated APCs (Fig. 3) . Two other monoclonal antibodies, one specific for HLA class II DR and one for class II DR+DP+DQ, were tested, but only a slight effect was noted for the DR-specific antibody (9 to 34%; data not shown). The HLA class II DQ-specific monoclonal antibody inhibited the SpeA mitogenicity by 78 to 90%, while PHA stimulation was not affected by the antibody (Fig. 3) . The lack of inhibition by the DR and DR+DP+DQ antibodies might be a result of binding of the antibodies to parts of the class II molecules other than the superantigen-interactive parts. On the other hand, both SpeA and SpeB as well as a streptococcus-derived protein have been shown previously to bind preferentially to DQ molecules (7, 21 (Fig. 4) . This is a unique VP specificity which is not shared with any of the staphylococcal enterotoxins or other Spes. Taken together with the HLA class II dependence, but not restriction, this clearly shows that SpeF is a novel group A streptococcal superantigen.
Prevalence of the SpeF gene in GAS isolates. GAS strains of 14 different serotypes, isolated from patients with different disease manifestations from 1930 to 1992, were tested for the presence of the speF, speA, and speB genes. The Southern blot technique using PCR-amplified probes specific for each toxin revealed that all 42 strains harbored the speF gene as well as the speB gene, while 12 (29%) strains lacked the speA gene (Table 1) . These frequencies are in agreement with previous findings that SpeA is phage encoded, while SpeB is chromosomally encoded (24) . That speF could be found in all strains tested suggested that the gene was chromosomally encoded. Figure 5 shows a Southern blot of HindIll-digested chromosomal DNA probed with a speF-specific gene fragment. A difference in fragment size could be detected between different serotypes, while in TlMl and T12M12 strains, the speF fragment was constant in size ( Fig. 5 and data not shown) . Thus, there was no extensive polymorphism in the speF gene region of the tested strains, which further supports the assumption that speF is chromosomally encoded.
An argument commonly used when discussing the clinical importance of the Spes in STSS has been that if the gene is found in all strains, including those isolated from bacteremia patients and patients with uncomplicated infections, the toxin cannot be of any clinical importance. However, we have previously reported that SpeB and SpeF are of clinical relevance since sera from septic patients had a significantly lower neutralizing capacity of the toxin mitogenicity than that of sera from patients with uncomplicated infections (41) . Our theory is that the specificity of the host humoral response as well as the reactivity of the immune cells of the patient will determine which particular toxin(s) produced by the infecting strain will be decisive for the clinical manifestation. Thus, we think that SpeB and SpeF can be equally as important in the development of STSS as other streptococcal superantigens.
